Prescott Group Capital Management L.L.C. Buys Shares of 306,838 Emergent BioSolutions Inc. (NYSE:EBS)

Prescott Group Capital Management L.L.C. bought a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 306,838 shares of the biopharmaceutical company’s stock, valued at approximately $2,255,000. Prescott Group Capital Management L.L.C. owned about 0.61% of Emergent BioSolutions as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Osaic Holdings Inc. increased its stake in Emergent BioSolutions by 139.5% during the 2nd quarter. Osaic Holdings Inc. now owns 5,667 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 3,301 shares during the period. Lazard Asset Management LLC acquired a new stake in Emergent BioSolutions in the 4th quarter valued at about $56,000. Covestor Ltd boosted its stake in shares of Emergent BioSolutions by 43.8% in the 1st quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 491 shares during the period. Ancora Advisors LLC purchased a new position in Emergent BioSolutions in the first quarter worth approximately $66,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Emergent BioSolutions in the 1st quarter valued at approximately $112,000. Hedge funds and other institutional investors own 88.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EBS. StockNews.com began coverage on shares of Emergent BioSolutions in a research note on Thursday, October 5th. They issued a “sell” rating for the company. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Emergent BioSolutions in a research report on Monday. Finally, Benchmark lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS traded up $0.02 on Monday, reaching $2.07. 394,838 shares of the company were exchanged, compared to its average volume of 1,746,386. The company has a 50-day moving average of $2.76 and a 200-day moving average of $5.69. The firm has a market cap of $107.25 million, a price-to-earnings ratio of -0.17 and a beta of 1.02. The company has a current ratio of 1.12, a quick ratio of 0.61 and a debt-to-equity ratio of 0.47. Emergent BioSolutions Inc. has a 1-year low of $1.81 and a 1-year high of $16.66.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care.